Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The hepatic stellate cell (HSC) activation pathway is a central mechanism in the development of liver fibrosis. In response to chronic liver injury, quiescent HSCs transdifferentiate into proliferative, contractile myofibroblast-like cells, leading to excessive extracellular matrix (ECM) deposition and tissue scarring. Key signaling pathways involved include TGF-β/Smad, MAPK, PI3K/AKT, Wnt/β-catenin, and NF-kB.
Targeting key signaling molecules within the pathway to reduce HSC activation, ECM production, and fibrosis progression.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatic Stellate Cell Activation Pathway.